دورية أكاديمية
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group
| العنوان: | A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group |
|---|---|
| المؤلفون: | G. Santini, C. De Souza, S. Aversa, C. Patti, L. Tedeschi, M. Candela, A. Olivieri, T. Chisesi, A. Rubagotti, R. Centurioni, V. Nardi, M. Congiu, M. Gennaro, M. Truini |
| المصدر: | Brazilian Journal of Medical and Biological Research, Vol 37, Iss 5, Pp 719-728 (2004) |
| بيانات النشر: | Associação Brasileira de Divulgação Científica, 2004. |
| سنة النشر: | 2004 |
| المجموعة: | LCC:Medicine (General) LCC:Biology (General) |
| مصطلحات موضوعية: | Localized aggressive non-Hodgkin's lymphoma, VACOP-B, Radiotherapy, Toxicity, Medicine (General), R5-920, Biology (General), QH301-705.5 |
| الوصف: | The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0100-879X 1414-431X |
| Relation: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004000500014; https://doaj.org/toc/0100-879X; https://doaj.org/toc/1414-431X |
| DOI: | 10.1590/S0100-879X2004000500014 |
| URL الوصول: | https://doaj.org/article/9efaa5000afe4941bb7930d225af2a80 |
| رقم الأكسشن: | edsdoj.9efaa5000afe4941bb7930d225af2a80 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 0100879X 1414431X |
|---|---|
| DOI: | 10.1590/S0100-879X2004000500014 |